Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mutant KRAS is a druggable target for pancreatic cancer
Elina Zorde Khvalevsky, Racheli Gabai, Itzhak H. Rachmut, et al.
Proceedings of the National Academy of Sciences (2013) Vol. 110, Iss. 51, pp. 20723-20728
Open Access | Times Cited: 276

Showing 1-25 of 276 citing articles:

Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
Sushrut Kamerkar, Valerie S. LeBleu, Hikaru Sugimoto, et al.
Nature (2017) Vol. 546, Iss. 7659, pp. 498-503
Open Access | Times Cited: 2159
Noncoding RNA therapeutics — challenges and potential solutions
Melanie Winkle, Sherien M. El‐Daly, Muller Fabbri, et al.
Nature Reviews Drug Discovery (2021) Vol. 20, Iss. 8, pp. 629-651
Open Access | Times Cited: 1123
Therapeutic siRNA: state of the art
Bo Hu, Liping Zhong, Yuhua Weng, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 1089
Molecular targeted therapy: Treating cancer with specificity
Yeuan Ting Lee, Yi Jer Tan, Chern Ein Oon
European Journal of Pharmacology (2018) Vol. 834, pp. 188-196
Closed Access | Times Cited: 866
RNA-Targeted Therapeutics
Stanley T. Crooke, Joseph L. Witztum, C. Frank Bennett, et al.
Cell Metabolism (2018) Vol. 27, Iss. 4, pp. 714-739
Open Access | Times Cited: 677
Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer
Louis Buscail, Barbara Bournet, Pierre Cordelier
Nature Reviews Gastroenterology & Hepatology (2020) Vol. 17, Iss. 3, pp. 153-168
Closed Access | Times Cited: 541
Pancreatic cancer: from state-of-the-art treatments to promising novel therapies
Ignacio Garrido‐Laguna, Manuel Hidalgo
Nature Reviews Clinical Oncology (2015) Vol. 12, Iss. 6, pp. 319-334
Closed Access | Times Cited: 533
Genetics and biology of pancreatic ductal adenocarcinoma
Haoqiang Ying, Prasenjit Dey, Wantong Yao, et al.
Genes & Development (2016) Vol. 30, Iss. 4, pp. 355-385
Open Access | Times Cited: 497
Strategies, design, and chemistry in siRNA delivery systems
Yizhou Dong, Daniel J. Siegwart, Daniel G. Anderson
Advanced Drug Delivery Reviews (2019) Vol. 144, pp. 133-147
Open Access | Times Cited: 449
Preclinical and clinical development of siRNA-based therapeutics
Gülnihal Özcan, Bülent Özpolat, Robert L. Coleman, et al.
Advanced Drug Delivery Reviews (2015) Vol. 87, pp. 108-119
Open Access | Times Cited: 424
Recent progress in development of siRNA delivery vehicles for cancer therapy
Hyun Jin Kim, Ahram Kim, Kanjiro Miyata, et al.
Advanced Drug Delivery Reviews (2016) Vol. 104, pp. 61-77
Open Access | Times Cited: 387
RNA-based therapeutics: an overview and prospectus
Yiran Zhu, Liyuan Zhu, Xian Wang, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 7
Open Access | Times Cited: 362
Pancreatic Cancer: Yesterday, Today and Tomorrow
Daniel Ansari, Bobby Tingstedt, Bodil Andersson, et al.
Future Oncology (2016) Vol. 12, Iss. 16, pp. 1929-1946
Open Access | Times Cited: 355
RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise?
Maggie Bobbin, John J. Rossi
The Annual Review of Pharmacology and Toxicology (2016) Vol. 56, Iss. 1, pp. 103-122
Open Access | Times Cited: 323
KRAS as a Therapeutic Target
Frank McCormick
Clinical Cancer Research (2015) Vol. 21, Iss. 8, pp. 1797-1801
Open Access | Times Cited: 307
RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges
Ai‐Ming Yu, Young Hee Choi, Mei‐Juan Tu
Pharmacological Reviews (2020) Vol. 72, Iss. 4, pp. 862-898
Open Access | Times Cited: 299
RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients
Talia Golan, Elina Zorde Khvalevsky, Ayala Hubert, et al.
Oncotarget (2015) Vol. 6, Iss. 27, pp. 24560-24570
Open Access | Times Cited: 288
Going beyond the liver: Progress and challenges of targeted delivery of siRNA therapeutics
Cornelia Lorenzer, Mehrdad Dirin, Anna-Maria Winkler, et al.
Journal of Controlled Release (2015) Vol. 203, pp. 1-15
Open Access | Times Cited: 263
RNAi-based therapeutics and tumor targeted delivery in cancer
Göknur Kara, George A. Călin, Bülent Özpolat
Advanced Drug Delivery Reviews (2022) Vol. 182, pp. 114113-114113
Closed Access | Times Cited: 253
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
Yunzhen Qian, Yitao Gong, Zhiyao Fan, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 247
Noncoding RNAs in cancer therapy resistance and targeted drug development
Wentao Wang, Cai Han, Yu-Meng Sun, et al.
Journal of Hematology & Oncology (2019) Vol. 12, Iss. 1
Open Access | Times Cited: 233
Small RNA combination therapy for lung cancer
Wen Xue, James E. Dahlman, Tuomas Tammela, et al.
Proceedings of the National Academy of Sciences (2014) Vol. 111, Iss. 34
Open Access | Times Cited: 223
KRAS mutation in pancreatic cancer
Ji Luo
Seminars in Oncology (2021) Vol. 48, Iss. 1, pp. 10-18
Open Access | Times Cited: 222
Nucleic acid delivery for therapeutic applications
Akash Gupta, Jason L. Andresen, Rajith S. Manan, et al.
Advanced Drug Delivery Reviews (2021) Vol. 178, pp. 113834-113834
Closed Access | Times Cited: 219
Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer
Pavan P. Adiseshaiah, Rachael M. Crist, Sara S. Hook, et al.
Nature Reviews Clinical Oncology (2016) Vol. 13, Iss. 12, pp. 750-765
Open Access | Times Cited: 215
Page 1 - Next Page

Scroll to top